Okuda-Arai Mina, Mori Sotaro, Takano Fumio, Ueda Kaori, Sakamoto Mari, Yamada-Nakanishi Yuko, Nakamura Makoto
Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Institute of Ophthalmology, University College London, London, UK.
Acta Ophthalmol. 2024 Mar;102(2):e178-e184. doi: 10.1111/aos.15750. Epub 2023 Sep 12.
The impact of various preoperative glaucoma medications on Schlemm's canal surgery outcomes remains unclear. This study aimed to investigate the impact of preoperative glaucoma medications on the postoperative 1-year outcomes of μTLO.
We analyzed the medical records of 218 patients who underwent their first μTLO to investigate the 1-year postoperative outcomes. Cox proportional hazard regression analysis was performed with surgical failure as the dependent variable and each type of preoperative medication as the independent variable. We also compared the 1-year outcomes of μTLO between users and non-users of specific medications using propensity score matching. Surgical success was defined as a postoperative intraocular pressure ranging from 5 to 21 mmHg, a ≥20% reduction in IOP from baseline, and no additional glaucoma surgery within 1 year postoperatively.
The Cox proportional hazard analysis showed that all drugs that do not increase the conventional outflow exhibited hazard ratios greater than 1.0, and the preoperative use of β-blockers and oral CAI was a significant surgical risk factor (hazard ratio: 2.65 and 2.45, p = 0.04 and <0.001). In the propensity score matching analysis, success rates at 1 year postoperatively were 55/85, 54/79, 60/73, and 40/76% for users/non-users of β-blockers, topical CAIs, an alpha-2 adrenergic agonist, and an oral CAI, respectively. Kaplan-Meier survival curves in these comparisons also demonstrated that preoperative β-blockers and oral CAI use were significant surgical risks (p = 0.01, <0.001).
Our study suggests that preoperative medications that do not involve conventional pathway outflow have a detrimental effect on subsequent Schlemm's canal surgery outcomes.
各种术前青光眼药物对施莱姆管手术结果的影响尚不清楚。本研究旨在调查术前青光眼药物对小梁网微管成形术(μTLO)术后1年结果的影响。
我们分析了218例首次接受μTLO手术患者的病历,以调查术后1年的结果。以手术失败作为因变量,每种术前药物作为自变量,进行Cox比例风险回归分析。我们还使用倾向得分匹配比较了特定药物使用者和非使用者的μTLO术后1年结果。手术成功定义为术后眼压在5至21 mmHg之间,眼压较基线降低≥20%,且术后1年内未进行额外的青光眼手术。
Cox比例风险分析显示,所有不增加传统房水流出的药物的风险比均大于1.0,术前使用β受体阻滞剂和口服碳酸酐酶抑制剂是显著的手术风险因素(风险比:2.65和2.45,p = 0.04和<0.001)。在倾向得分匹配分析中,β受体阻滞剂、局部碳酸酐酶抑制剂、α2肾上腺素能激动剂和口服碳酸酐酶抑制剂的使用者/非使用者术后1年的成功率分别为55/85、54/79、60/73和40/76%。这些比较中的Kaplan-Meier生存曲线也表明,术前使用β受体阻滞剂和口服碳酸酐酶抑制剂是显著的手术风险(p = 0.01,<0.001)。
我们的研究表明,不涉及传统房水流出途径的术前药物对随后的施莱姆管手术结果有不利影响。